Edgewise Therapeutics Inc(EWTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 2 at 4:00 PM ET (Korea 11/3 06:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.85 | Insider Own | 24.57% | Shs Outstand | 107.8M | Perf Week | -2.73% |
| Market Cap | 4.14B | Forward P/E | - | EPS next Y | 16.77% | Insider Trans | -1.11% | Shs Float | 81.9M | Perf Month | -7.97% |
| Enterprise Value | 3.68B | PEG | - | EPS next Q | -0.52 | Inst Own | 87.23% | Short Float | 14.35% | Perf Quarter | -14.77% |
| Income | -0.20B | P/S | - | EPS this Y | -26.01% | Inst Trans | -0.21% | Short Ratio | 8.11 | Perf Half Y | 21.14% |
| Sales | 0.00B | P/B | 9.16 | EPS next 5Y | -3.58% | ROA | -36.09% | Short Interest | 11.75M | Perf YTD | 53.54% |
| Book/sh | 4.16 | P/C | 8.98 | EPS past 3/5Y | -8.91% -36.19% | ROE | -38.03% | 52W High | -21.46% ($48.51) | Perf Year | 108.42% |
| Cash/sh | 4.24 | P/FCF | - | Sales past 3/5Y | - | ROIC | -43.76% | 52W Low | 128.14% ($16.70) | Perf 3Y | 479.91% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -18.88% | Gross Margin | - | Volatility(W/M) | 4.84% 4.62% | Perf 5Y | 111.9% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.92 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.24 | EPS Q/Q | -54.68% | Profit Margin | - | RSI (14) | 42.35 | Recom | 1.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.24 | Sales Q/Q | - | SMA20 | -1.9% ($38.84) | Beta | 0.4 | Target Price | $54 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -7.57% ($41.22) | Rel Volume | 0.75 | Prev Close | $38.9 |
| Employees | 146 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -13.32% - | SMA200 | 4.86% ($36.33) | Avg Volume(3M) | 1.45M | Price | $38.1 |
| IPO | 2021/3/26 | Option/Short | Yes/Yes | Trades | 10916 | Volume | 1,083,632 | Change | -2.06% |
🫀 A clinical-stage biotech company developing therapeutics for cardiovascular diseases. It is developing oral treatments targeting cardiovascular conditions such as hypertrophic cardiomyopathy and heart failure, focusing its cardiovascular pipeline with funds secured through the divestiture of its muscle disease business. A biotech firm specializing in cardiovascular therapeutics.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
EWTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -26.0% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +111.9%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 87.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #56 of 597 in the industry
Based on market cap of $4B.
DFTX#55 Definium Therapeutics Inc $4B PER - EWTX#56 Edgewise Therapeutics Inc $4B PER - 
LEGN#57 Legend Biotech Corp ADR $4B PER - 
ARQT#58 Arcutis Biotherapeutics Inc $4B PER 150.9 
RLAY#59 Relay Therapeutics Inc $4B PER - 
FAQ
What kind of company is EWTX?
EWTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EWTX?
The market cap of EWTX is approximately $4.1B, ranking 1,509 within its sector.
What is the 52-week high and low for EWTX?
EWTX has recorded a 52-week high of $48.51 and a low of $16.70.
